181 related articles for article (PubMed ID: 16000280)
21. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT.
Davis MR; Votaw JR; Bremner JD; Byas-Smith MG; Faber TL; Voll RJ; Hoffman JM; Grafton ST; Kilts CD; Goodman MM
J Nucl Med; 2003 Jun; 44(6):855-61. PubMed ID: 12791810
[TBL] [Abstract][Full Text] [Related]
22. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging.
Pirker W; Asenbaum S; Hauk M; Kandlhofer S; Tauscher J; Willeit M; Neumeister A; Praschak-Rieder N; Angelberger P; Brücke T
J Nucl Med; 2000 Jan; 41(1):36-44. PubMed ID: 10647603
[TBL] [Abstract][Full Text] [Related]
23. Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: evaluation of reference tissue models.
Seki C; Ito H; Ichimiya T; Arakawa R; Ikoma Y; Shidahara M; Maeda J; Takano A; Takahashi H; Kimura Y; Suzuki K; Kanno I; Suhara T
Ann Nucl Med; 2010 May; 24(4):249-60. PubMed ID: 20364374
[TBL] [Abstract][Full Text] [Related]
24. Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects.
Laruelle M; Wallace E; Seibyl JP; Baldwin RM; Zea-Ponce Y; Zoghbi SS; Neumeyer JL; Charney DS; Hoffer PB; Innis RB
J Cereb Blood Flow Metab; 1994 Nov; 14(6):982-94. PubMed ID: 7929662
[TBL] [Abstract][Full Text] [Related]
25. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
[TBL] [Abstract][Full Text] [Related]
26. SPECT of serotonin transporters using 123I-ADAM: optimal imaging time after bolus injection and long-term test-retest in healthy volunteers.
Catafau AM; Pérez V; Penengo MM; Bullich S; Danús M; Puigdemont D; Pascual JC; Corripio I; Llop J; Perich J; Alvarez E
J Nucl Med; 2005 Aug; 46(8):1301-9. PubMed ID: 16085586
[TBL] [Abstract][Full Text] [Related]
27. Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm.
Habraken JB; Booij J; Slomka P; Sokole EB; van Royen EA
J Nucl Med; 1999 Jul; 40(7):1091-7. PubMed ID: 10405125
[TBL] [Abstract][Full Text] [Related]
28. Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I.
Varrone A; Tóth M; Steiger C; Takano A; Guilloteau D; Ichise M; Gulyás B; Halldin C
J Nucl Med; 2011 Jan; 52(1):132-9. PubMed ID: 21189414
[TBL] [Abstract][Full Text] [Related]
29. 123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibility.
Staley JK; van Dyck CH; Weinzimmer D; Brenner E; Baldwin RM; Tamagnan GD; Riccardi P; Mitsis E; Seibyl JP
J Nucl Med; 2005 Sep; 46(9):1466-72. PubMed ID: 16157529
[TBL] [Abstract][Full Text] [Related]
30. Whole-body distribution and radiation dosimetry of the dopamine transporter radioligand [(11)C]PE2I in healthy volunteers.
Ribeiro MJ; Ricard M; Lièvre MA; Bourgeois S; Emond P; Gervais P; Dollé F; Syrota A
Nucl Med Biol; 2007 May; 34(4):465-70. PubMed ID: 17499737
[TBL] [Abstract][Full Text] [Related]
31. Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-m ethylph enyl)nortropane (PE2I).
Guilloteau D; Emond P; Baulieu JL; Garreau L; Frangin Y; Pourcelot L; Mauclaire L; Besnard JC; Chalon S
Nucl Med Biol; 1998 May; 25(4):331-7. PubMed ID: 9639293
[TBL] [Abstract][Full Text] [Related]
32. MRI-guided region-of-interest delineation is comparable to manual delineation in dopamine transporter SPECT quantification in patients: a reproducibility study.
Ziebell M; Pinborg LH; Thomsen G; de Nijs R; Svarer C; Wagner A; Knudsen GM
J Nucl Med Technol; 2010 Jun; 38(2):61-8. PubMed ID: 20484180
[TBL] [Abstract][Full Text] [Related]
33. Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects.
Kuikka JT; Tupala E; Bergström KA; Hiltunen J; Tiihonen J
Eur J Nucl Med; 1999 Nov; 26(11):1486-8. PubMed ID: 10552092
[TBL] [Abstract][Full Text] [Related]
34. A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([11C]AFM).
Huang Y; Hwang DR; Bae SA; Sudo Y; Guo N; Zhu Z; Narendran R; Laruelle M
Nucl Med Biol; 2004 Jul; 31(5):543-56. PubMed ID: 15219271
[TBL] [Abstract][Full Text] [Related]
35. Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters.
Seibyl JP; Laruelle M; van Dyck CH; Wallace E; Baldwin RM; Zoghbi S; Zea-Ponce Y; Neumeyer JL; Charney DS; Hoffer PB; Innis RB
J Nucl Med; 1996 Feb; 37(2):222-8. PubMed ID: 8667048
[TBL] [Abstract][Full Text] [Related]
36. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.
Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923
[TBL] [Abstract][Full Text] [Related]
37. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
[TBL] [Abstract][Full Text] [Related]
38. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease.
Chalon S; Emond P; Bodard S; Vilar MP; Thiercelin C; Besnard JC; Guilloteau D
Synapse; 1999 Feb; 31(2):134-9. PubMed ID: 10024010
[TBL] [Abstract][Full Text] [Related]
39. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT.
Abi-Dargham A; Gandelman MS; DeErausquin GA; Zea-Ponce Y; Zoghbi SS; Baldwin RM; Laruelle M; Charney DS; Hoffer PB; Neumeyer JL; Innis RB
J Nucl Med; 1996 Jul; 37(7):1129-33. PubMed ID: 8965183
[TBL] [Abstract][Full Text] [Related]
40. Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I.
Hall H; Halldin C; Guilloteau D; Chalon S; Emond P; Besnard J; Farde L; Sedvall G
Neuroimage; 1999 Jan; 9(1):108-16. PubMed ID: 9918732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
